Recent developments in the legal battle over the planned $3.3 billion UnitedHealth Group (NYSE: UHG) acquisition of Amedisys (Nasdaq: AMED) have moved the ...

Total net sales for Q1 2025 were $5.1 million, reflecting a 12% sequential increase from the prior quarter. E-commerce sales contributed $3.9 million, representing 77% of total net sales, while ...

We recently published a list of Top 10 Must-See AI News And Ratings For Investors. In this article, we are going to take a ...

Pro Medicus is in a strong financial position. As of June 2024, it had AUD 155 million in net cash, and we forecast the company to continue holding net cash over our explicit 10-year forecast period.

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.